Oncolytics Biotech Inc. (Oncolytics) is a development stage biopharmaceutical company that focuses on the discovery and development of pharmaceutical products for the treatment of cancers that have not been successfully treated with conventional therapeutics. The Company is focused on the research and development of one product, REOLYSIN, for human application. REOLYSIN is the Company’s potential cancer therapeutic. Its products under development have not been manufactured on a commercial scale. The Company’s potential product for human use, REOLYSIN, is developed from the reovirus. This virus has been demonstrated to replicate specifically in tumour cells bearing an activated Ras pathway. In April 2009, Oncolytics completed the acquisition of an inactive private company.